Literature DB >> 3426349

Comparative local anaesthetic and antiarrhythmic actions of levamisole hydrochloride and lignocaine hydrochloride.

G Onuaguluchi1, I N Igbo.   

Abstract

Using the guinea-pig wheal preparation for determining the degree of infiltration anaesthesia, lignocaine was found to be 2 times more potent than levamisole. Lignocaine was, however, 1.27 times more toxic than levamisole in the mouse. It is suggested that levamisole could be used as a local anaesthetic agent for infiltration anaesthesia. As regards surface anaesthesia, lignocaine was 16.6 times more potent than levamisole. Levamisole would, therefore, not be of use in surface anaesthesia. Levamisole was more effective than lignocaine in protecting toads against deaths due to the minimum dose of ouabain which caused 100% mortality. The therapeutic indices for levamisole and lignocaine were 4.57 and 1.58 respectively. Unlike with lignocaine it was possible to achieve more than 50% protection with levamisole. Levamisole was, however, only marginally more effective than lignocaine in reverting to sinus rhythm, barium chloride-induced ventricular dysrhythmia in the rat. It is suggested that levamisole could have potential value as an antiarrhythmic agent.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3426349

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  3 in total

1.  Alkaline Phosphatase Inhibitors Attenuate Renovascular Responses to Norepinephrine.

Authors:  Edwin K Jackson; Yumeng Zhang; Dongmei Cheng
Journal:  Hypertension       Date:  2017-01-30       Impact factor: 10.190

Review 2.  Semen as a rich source of diagnostic biomarkers for prostate cancer: latest evidence and implications.

Authors:  Chenyu Mao; Yongfeng Ding; Nong Xu
Journal:  Mol Cell Biochem       Date:  2021-10-16       Impact factor: 3.396

3.  Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study.

Authors:  Jérémy T Campillo; Céline Eiden; Michel Boussinesq; Sébastien D S Pion; Jean-Luc Faillie; Cédric B Chesnais
Journal:  Br J Clin Pharmacol       Date:  2021-09-15       Impact factor: 3.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.